{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T08:32:16Z","timestamp":1771662736236,"version":"3.50.1"},"reference-count":17,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:00:00Z","timestamp":1676332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Novel anti-EGFR therapies target resistance to standard-of-care anti-EGFR in patients with metastatic lung cancer. We describe tumors at progression versus at the initiation of novel anti-EGFR agents in patients with metastatic lung adenocarcinoma harboring EGFR mutation. This clinical case series reports the histological and genomic features and their evolution following disease progression under amivantamab or patritumab-deruxtecan in clinical trials. All patients had a biopsy at disease progression. Four patients harboring EGFR gene mutations were included. Three of them received anterior anti-EGFR treatment. Median delay to disease progression was 15 months (range: 4\u201324). At progression, all tumors presented a mutation in the TP53 signaling pathway associated with a loss of heterozygosis (LOH) of the allele in 75% (n = 3), and two tumors (50%) presented an RB1 mutation associated with LOH. Ki67 expression increased above 50% (range 50\u201390%) in all samples compared to baseline (range 10\u201330%), and one tumor expressed a positive neuroendocrine marker at progression. Our work reports the potential molecular mechanisms of resistance under novel anti-EGFR in patients with metastatic EGFR-mutated lung adenocarcinoma, with the transformation to a more aggressive histology with acquired TP53 mutation and\/or the increase in Ki67 expression. These characteristics are usually found in aggressive Small Cell Lung Cancer.<\/jats:p>","DOI":"10.3390\/ijms24043802","type":"journal-article","created":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T02:31:23Z","timestamp":1676428283000},"page":"3802","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Gain of Aggressive Histological and Molecular Patterns after Acquired Resistance to Novel Anti-EGFR Therapies in Non-Small Cell Lung Cancer"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0523-0310","authenticated-orcid":false,"given":"Cl\u00e9mence","family":"Basse","sequence":"first","affiliation":[{"name":"Institut du Thorax Curie Montsouris, 75005 Paris, France"},{"name":"Paris Saclay Campus, Versailles Saint Quentin University, 78000 Versailles, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olfa","family":"Trabelsi-Grati","sequence":"additional","affiliation":[{"name":"Genetics Department, Institut Curie, 75005 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5596-3926","authenticated-orcid":false,"given":"Julien","family":"Masliah","sequence":"additional","affiliation":[{"name":"Genetics Department, Institut Curie, 75005 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9line","family":"Callens","sequence":"additional","affiliation":[{"name":"Genetics Department, Institut Curie, 75005 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maud","family":"Kamal","sequence":"additional","affiliation":[{"name":"Department of Drug Development and Innovation, Institut Curie, 75005 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Freneaux","sequence":"additional","affiliation":[{"name":"Pathology Department, Institut Curie, 75005 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9706-7241","authenticated-orcid":false,"given":"Jerzy","family":"Klijanienko","sequence":"additional","affiliation":[{"name":"Pathology Department, Institut Curie, 75005 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Bieche","sequence":"additional","affiliation":[{"name":"Genetics Department, Institut Curie, 75005 Paris, France"},{"name":"Genetics Department, University Paris Descartes, 75005 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[{"name":"Institut du Thorax Curie Montsouris, 75005 Paris, France"},{"name":"Paris Saclay Campus, Versailles Saint Quentin University, 78000 Versailles, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,14]]},"reference":[{"key":"ref_1","unstructured":"(2015, June 30). National Comprehensive Cancer Network. Non-Small Cell Lung Cancer (Version 7.2015). Available online: http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1470-2045(10)70087-5","article-title":"New driver mutations in non-small-cell lung cancer","volume":"12","author":"Pao","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/annonc\/mdy554","article-title":"PanAsian adapted clinical practice guidelines for the management of patients with metastatic non-small-cell lung cancer: A CSCO ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS","volume":"30","author":"Wu","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"695","DOI":"10.21037\/tlcr.2016.12.02","article-title":"Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: Review on emerged mechanisms of resistance","volume":"5","author":"Minari","year":"2016","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in Untreated EGFR-Mutated Advanced Non\u2013Small-Cell Lung Cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.jtho.2018.06.019","article-title":"Diverse EGFR exon 20 insertions and co-occurring molecular alterations identified by comprehensive genomic profiling of NSCLC","volume":"13","author":"Riess","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature14664","article-title":"Comprehensive genomic profiles of small cell lung cancer","volume":"524","author":"Goerge","year":"2015","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1200\/JCO.21.00662","article-title":"Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study","volume":"39","author":"Park","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1158\/2159-8290.CD-21-0715","article-title":"Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer","volume":"12","author":"Janne","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"930731","DOI":"10.3389\/fonc.2022.930731","article-title":"Integrated molecular and pharmacological characterization of patient derived xenografts from bladder and ureteral cancers identifies new potential therapies","volume":"12","author":"Lang","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.molcel.2016.08.002","article-title":"53BP1 Integrates DNA Repair and p53-Dependent Cell Fate Decisions via Distinct Mechanisms","volume":"64","author":"Oliveira","year":"2016","journal-title":"Mol. Cell."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5975","DOI":"10.1038\/s41388-021-01991-3","article-title":"Spontaneous and inherited TP53 genetic alterations","volume":"40","author":"Levine","year":"2021","journal-title":"Oncogene"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1016\/S1470-2045(14)71180-5","article-title":"Transformation from non-small-cell lung cancer to small-cell lung cancer: Molecular drivers and cells of origin","volume":"16","author":"Oser","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jtho.2018.10.150","article-title":"Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC","volume":"14","author":"Kim","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Canale, M., Petracc, E., Delmonte, A., Bronte, G., Chiadini, E., Ludovini, V., Dubini, A., Papi, M., Baglivo, S., and De Luigi, N. (2020). Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs. J. Clin. Med., 9.","DOI":"10.3390\/jcm9041047"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.jtho.2019.06.002","article-title":"Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes","volume":"14","author":"Offin","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"642190","DOI":"10.3389\/fonc.2021.642190","article-title":"Small Cell Lung Cancer Transformation as a Resistance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review","volume":"11","author":"Leonetti","year":"2021","journal-title":"Front. Oncol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/4\/3802\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:34:49Z","timestamp":1760121289000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/4\/3802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,14]]},"references-count":17,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["ijms24043802"],"URL":"https:\/\/doi.org\/10.3390\/ijms24043802","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,14]]}}}